Tad Carter

My Blog

2020 14/Aug

BREAKING NEWS: U.S. FDA Oncologic Drugs Advisory Committee voted nine to one in favor of Mesoblast’s remestemcel-L (Ryoncil™) for efficacy in children with steroid-refractory acute graft versus host disease (SR-aGVHD). This is an important milestone for allogenic cell therapies being developed to treat critical inflammatory diseases, including #COVID19. RYONCIL has been accepted for Priority Review by […]

Keep Reading